Company is advancing a clinical-stage novel immunotherapy based on technology developed with the support of IRICoR
MONTREAL, QC, September 11, 2017 – SpecificiT Pharma Inc., a privately held Montreal-based biopharmaceutical company focused on developing innovative personalized hematological cancer immunotherapies, is pleased to announce the completion of a seed financing by existing shareholder AmorChem, along with new partners, Sanderling Ventures and Accel-Rx Health Sciences Accelerator. The proceeds of the transaction will be used to complete key activities with respect to manufacturing, process development and the addition of key management. Pierre Beauparlant, Ph.D., Venture Partner at Sanderling Ventures, will assume the role of Chief Executive Officer of the company. To see the news click here.